Vizz

Do not take it if

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

• Instill one drop in each eye, wait 2 minutes and instill a second drop in each eye once daily ( 2 ).
• 2.1 Recommended Dosage Instill one drop in each eye, wait 2 minutes and instill a second drop in each eye once daily from the same single-dose vial.
• 2.2 Administration Instructions Contact lenses should be removed prior to the instillation of VIZZ and may be reinserted 10 minutes after instillation.
• If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
• To open vial, twist off top [see How Supplied/Storage and Handling (16.1) ] .
• Discard the opened single-dose vial after use.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Quoted from the official label, section “Overdosage”.

Use in children

Presbyopia does not occur in the pediatric population.

Quoted from the official label, section “Pediatric Use”.

Use in older people

No overall differences in safety or effectiveness of VIZZ have been observed between patients 65 years of age and older and younger adult patients.

Quoted from the official label, section “Geriatric Use”.

Side effects

• The most common adverse reactions were instillation site irritation (20%), dim vision (16%), and headache (13%) ( 6.1 ).
• To report SUSPECTED ADVERSE REACTIONS, contact LENZ Therapeutics, Inc. at 1-888-711-LENZ or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
• 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
• VIZZ dosed once daily was evaluated for safety and efficacy in 466 participants with presbyopia in 2 randomized, double-masked, controlled phase 3 studies for 42 days (CLARITY-1, NCT05656027 and CLARITY-2, NCT05728944).
• VIZZ dosed once daily was also evaluated for long term safety in 217 participants with presbyopia in a separate randomized, double-masked, controlled phase 3 study (CLARITY-3, NCT05753189) for a 6-month duration.
• The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%).
• Adverse reactions reported in > 5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%).
• The majority of adverse reactions were mild, transient, and self-resolving.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

• Night Driving Advise patients that they may experience temporary dim or dark vision.
• Advise patients to exercise caution with night driving and when hazardous activities are undertaken in poor illumination [see Warnings and Precautions (5.1) ].
• Blurred Vision Temporary problems when changing focus between near and distant objects may occur.
• Advise patients not to drive or use machinery if vision is not clear (e.g., blurred vision) [see Warnings and Precautions (5.1) ] .
• When to Seek Physician Advice Advise patients to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss [see Warnings and Precautions (5.2) ].
• Contact Lens Wear Advise patients to remove contact lenses prior to the instillation of VIZZ.
• Wait 10 minutes after instillation before reinserting their contact lenses [see Warnings and Precautions (5.5) ].
• Potential for Eye Injury or Contamination Advise patients to
• avoid touching the tip of the single-dose vial to the eye or to any other surface in order to prevent eye injury or contamination [see Warnings and Precautions (5.6) ].
• Advise patients to discard the opened single-dose vial and any remaining contents after use.
• Concomitant Topical Ocular Therapy Advise patients if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart [see Dosage and Administration (2) ] .

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

• FORMS AND STRENGTHS VIZZ is a clear to opalescent and colorless to slightly yellow ophthalmic solution containing 1.44% of aceclidine in a single-dose vial. Ophthalmic solution:
• aceclidine 1.44% in a single-dose vial ( 3 ).

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

• 16.1 How Supplied VIZZ (aceclidine ophthalmic solution) 1.44% is supplied as a sterile, clear to opalescent, colorless to slightly yellow, and viscous ophthalmic solution in configurations of 5 single-dose vials.
• VIZZ does not include antimicrobial preservatives.
• Each single-dose vial is comprised of transparent low-density polyethylene (LDPE). 5 single-dose vials are packaged in a foil pouch.
• VIZZ is supplied in:
• NDC Number Description Vial Configuration 84226-100-11 carton box of 25 single-dose vials (5 pouches x five vials of 0.4 mL each) 84226-100-21 carton box of 25 single-dose vials (5 pouches x five vials of 0.25 mL each) Figure Figure
• 16.2 Storage and Handling Store refrigerated at 36°F to 46°F (2°C to 8°C).
• Do not freeze.
• When stored in refrigerated conditions, VIZZ can be used until the expiration date.
• Once pouch or vial(s) are removed from refrigeration, VIZZ may be stored at room temperature [up to 77°F (25°C)] but must be used within 30 days.
• Discard the opened single-dose vial after use.
• During shipment, VIZZ may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.

Quoted from the official label, section “How Supplied”.

How to store it

• Store refrigerated at 36°F to 46°F (2°C to 8°C).
• Do not freeze.
• When stored in refrigerated conditions, VIZZ can be used until the expiration date.
• Once pouch or vial(s) are removed from refrigeration, VIZZ may be stored at room temperature [up to 77°F (25°C)] but must be used within 30 days.
• Discard the opened single-dose vial after use.
• During shipment, VIZZ may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.

Quoted from the official label, section “Storage and Handling”.

What is in it

• VIZZ (aceclidine ophthalmic solution) 1.44% is a cholinergic muscarinic receptor agonist supplied as a sterile, clear to opalescent, colorless to slightly yellow, and viscous ophthalmic solution containing 1.75% of aceclidine hydrochloride (equivalent to 1.44% aceclidine).
• The chemical names for aceclidine hydrochloride are:
• 1) 3-Acetoxyquinuclidine Hydrochloride; 2) 3-Quinuclidinyl Acetate Hydrochloride.
• Its molecular weight is 205.68 g/mol and its molecular formula is C 9 H 15 NO 2 ∙ HCl.
• Each mL of VIZZ contains aceclidine hydrochloride 1.75% (17.82 mg) as the active ingredient.
• Inactive ingredients in the ophthalmic solution are:
• polysorbate 80, mannitol, hypromellose, edetate disodium dihydrate, sodium citrate dihydrate, water for injection, and may also include hydrochloric acid and/or sodium hydroxide for pH adjustment to between 4.5 and 5.5, if necessary.
• VIZZ does not contain antimicrobial preservatives.
• Chemical Structure

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

Details

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page